RODRIGO BUENO DE OLIVEIRA

(Fonte: Lattes)
Índice h a partir de 2011
10
Projetos de Pesquisa
Unidades Organizacionais
LIM/16 - Laboratório de Fisiopatologia Renal, Hospital das Clínicas, Faculdade de Medicina

Resultados de Busca

Agora exibindo 1 - 6 de 6
  • bookPart
    Litíase renal
    (2013) OLIVEIRA, Rodrigo Bueno
  • bookPart
    MicroRNAs: a bigger role for small ribonucleic acids in kidney diseases
    (2014) SANTOS, Ana Mondadori dos; OLIVEIRA, Rodrigo Bueno; METZINGER, Laurent
  • bookPart
    Doença renal crônica
    (2013) OLIVEIRA, Rodrigo Bueno
  • article 21 Citação(ões) na Scopus
    Pharmacotherapy of chronic kidney disease and mineral bone disorder
    (2011) BARRETO, Fellype Carvalho; OLIVEIRA, Rodrigo Azevedo de; OLIVEIRA, Rodrigo Bueno; JORGETTI, Vanda
    Introduction: Disturbances of the bone and mineral metabolism are a common complication of chronic kidney disease (CKD); these disturbances are known as CKD-mineral bone disorder (CKD-MBD). A better understanding of the pathophysiological mechanisms of CKD-MBD, along with its negative impact on other organs and systems, as well as on survival, has led to a shift in the treatment paradigm of this disorder. The use of phosphate binders changed dramatically over the last decade when noncalcium-containing phosphate binders, such as sevelamer and lanthanum carbonate, became possible alternative treatments to avoid calcium overload. Vitamin D receptor activators, such as paricalcitol and doxercalciferol, with fewer calcemic and phosphatemic effects, have also been introduced to control parathormone production and the interest in native vitamin D supplementation has grown. Furthermore, a new drug class, the calcimimetics, has recently been introduced into the therapeutic arsenal for treating secondary hyperparathyroidism. Areas covered: This review discusses the advantages and disadvantages of the above pharmacological options to treat CKD-MBD. Expert opinion: The individual-based use of phosphate binders, vitamin D and calcimimetics, separately or in combination, constitute a reasonable approach to treat CKD-MBD. These treatments aim to achieve a rigorous control of phosphorus and parathormone levels, while avoiding calcium overload.
  • bookPart
    Vascular calcification in chronic kidney disease: the role of the calcium-sensing receptor
    (2014) HéNAUT, Lucie; LOUVET, Loïc; OLIVEIRA, Rodrigo Bueno
  • bookPart
    Litíase renal
    (2016) OLIVEIRA, Rodrigo Bueno; GOMES, Samirah Abreu